MBIO - MUSTANG BIO, INC.

0.8963
-0.053   -5.913%

Share volume: 39,560
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.26%

PREVIOUS CLOSE
CHG
CHG%
$0.95
-0.05
-0.06%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
15%
Profitability 8%
Dept financing 6%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-6.38%
1 Month
8.42%
3 Months
-28.30%
6 Months
-34.10%
1 Year
-39.44%
2 Year
-35.52%
Key data
Stock price
$0.90
P/E Ratio 
0.00
DAY RANGE
$0.88 - $0.93
EPS 
-$1.87
52 WEEK RANGE
$0.53 - $7.00
52 WEEK CHANGE
-$40.25
MARKET CAP 
11.004 M
YIELD 
N/A
SHARES OUTSTANDING 
7.299 M
DIVIDEND
$0.00
EX-DIVIDEND DATE
01-16-2025
NEXT EARNINGS DATE
04-29-2025
BETA 
37.22
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$37,147
AVERAGE 30 VOLUME 
$391,985
Company detail
CEO: Manuel Litchman
Region: US
Website: mustangbio.com
Employees: 100
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition.

Recent news